Assenagon Asset Management
SWTX

Assenagon Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Assenagon Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-79,640
Closed -$3.51M – 1237
2025
Q1 		$3.51M Buy
+79,640
New +$3.67M 0.01% 609
2024
Q3 		– Sell
-50,978
Closed -$1.92M – 1478
2024
Q2 		$1.92M Hold
50,978
– – ﹤0.01% 918
2024
Q1 		$2.51M Buy
+50,978
New +$2.36M 0.01% 803

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Assenagon Asset Management's SWTX Position: Q2 2025 in Review

Assenagon Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 79,640 shares — an estimated $3.51M sold.

Assenagon Asset Management first reported a position in SWTX in Q1 2024 and held it in 3 quarters. The position peaked at $3.51M in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Assenagon Asset Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 79,640 SpringWorks Therapeutics shares in Q2 2025, an estimated $3.51M.
  • Assenagon Asset Management first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 3 quarters.
  • Assenagon Asset Management's SpringWorks Therapeutics position peaked at $3.51M in Q1 2025.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Assenagon Asset Management's 13F filing for Q2 2025, filed 11 Jul 2025.